U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C34H33N3O5
Molecular Weight 563.6442
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELACRIDAR

SMILES

COc1cccc2c1[nH]c3c(cccc3C(=O)Nc4ccc(cc4)CCN5CCc6cc(c(cc6C5)OC)OC)c2=O

InChI

InChIKey=OSFCMRGOZNQUSW-UHFFFAOYSA-N
InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

HIDE SMILES / InChI

Molecular Formula C34H33N3O5
Molecular Weight 563.6442
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB04881

Elacridar is an oral bioenhancer that targets multiple drug resistance in tumors. Elacridar is a strong and relatively specific inhibitor of P-gp and BCRP, two main efflux transporters. Development of elacridar is assumed to have been discontinued.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in mouse. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
70.0 nM [IC50]
0.31 µM [IC50]
Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
185 μg/L
1000 mg 1 times / week multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: TOPOTECAN
ELACRIDAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2629 μg × h/L
1000 mg 1 times / week multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: TOPOTECAN
ELACRIDAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
1000 mg 1 times / week multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / week
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / week
Co-administed with::
topotecan(1000 mg of elacridar on days 1 and 8 1 h before or simultaneously with 2.0 mg oral topotecan)
Sources: Page: p.3279
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FED
Population Size: 4
Sources: Page: p.3279
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparison of drug efflux transport kinetics in various blood-brain barrier models.
2006 Jun
Mechanisms underlying saturable intestinal absorption of metformin.
2008 Aug
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.
2009 Mar
Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.
2010 Oct
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
2010 Sep
Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux.
2012 May 1
Patents

Sample Use Guides

The starting daily dose of GF120918 was 50 mg and was to be increased in subsequent cohorts until a steady state plasma level of 100 ng/ml was reached.
Route of Administration: Oral
In Caki-1 and ACHN cells, elacridar ( 2.5 μM) significantly inhibits the cell growth. The P-glycoprotein expression is found to be inhibited by 5 uM elacridar in all cell lines (786-O, ACHN, and Caki-1).
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:24:01 UTC 2021
Edited
by admin
on Sat Jun 26 06:24:01 UTC 2021
Record UNII
N488540F94
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELACRIDAR
INN   WHO-DD  
INN  
Official Name English
ELACRIDAR [INN]
Common Name English
4-ACRIDINECARBOXAMIDE, N-(4-(2-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLINYL)ETHYL)PHENYL)-9,10-DIHYDRO-5-METHOXY-9-OXO-
Systematic Name English
LY-335979
Code English
4'-(2-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLYL)ETHYL)-5-METHOXY-9-OXO-4-ACRIDANCARBOXANILIDE
Systematic Name English
ELACRIDAR [WHO-DD]
Common Name English
LY335979
Code English
Classification Tree Code System Code
NCI_THESAURUS C1744
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
Code System Code Type Description
CAS
143664-11-3
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
INN
7582
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
EVMPD
SUB06475MIG
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
ChEMBL
CHEMBL396298
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
NCI_THESAURUS
C73318
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
DRUG BANK
DB04881
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
FDA UNII
N488540F94
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
PUBCHEM
119373
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
MESH
C083501
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
EPA CompTox
143664-11-3
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INDUCER
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY